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Abstract. Gallic acid (GA), a polyphenol, is widely found
in numerous fruits and vegetables, particularly in hickory
nuts. In the present study, we found that gallic acid, a natural
phenolic compound isolated from fruits and vegetables, had
a more potent growth inhibitory effect on two ovarian cancer
cell lines, OVCAR-3 and A2780/CP70, than the effect on a
normal ovarian cell line, IOSE-364. These results demonstrated that GA selectively inhibits the growth of cancer cells.
Gene expression was examined by ELISA and western blot
analysis, and gene pathways were examined by luciferase
assay. It was found that GA inhibited VEGF secretion and
suppressed in vitro angiogenesis in a concentration-dependent
manner. GA downregulated AKT phosphorylation as well
as HIF-1α expression but promoted PTEN expression. The
luciferase assay results suggest that the PTEN/AKT/HIF-1α
pathway accounts for the inhibitory effect of GA on VEGF
expression and in vitro angiogenesis. These findings provide
strong support for the high potential of GA in the prevention
and therapy of ovarian cancer.
Introduction
Epidemiological studies have demonstrated that diets rich in
fruits and vegetables have a chemopreventive effect on the
development of cancer. It has been reported that phenolic
compounds, a large family of natural compounds, abundant
in fruits and vegetables, have been associated with a possible
reduced risk of prostate cancer (1), breast cancer (2), liver
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cancer (3) and cervical cancer (4). The potential application of
phenolic compounds in the development of therapeutic agents
for cancer treatment and for their use as valuable additive
or nutritional supplements to prevent cancer risk has gained
increasing importance, and research in this field is currently
expanding (5-7).
Ovarian cancer is one of the leading causes of cancerrelated mortality in women in developed areas (8). In 2015, an
estimated 21,290 new cases and 14,180 deaths due to ovarian
cancer occurred in the USA (9). Unfortunately, the overall
survival rate at 5 years is only 50%, which has not significantly
improved in the past 30 years (10). Even though the majority of
women have successful initial therapy, the low rate of survival
is due to eventual recurrence and succumbing to the disease.
The treatment for ovarian cancer is still unsatisfactory, and
new treatments for patients with recurrent ovarian cancer
who are incurable with current management are needed.
Another challenge is that more than 70% of women present
with advanced stage disease (11). Symptoms of the disease
generally do not present themselves until after the cancer has
metastasized from the ovaries to the surfaces of the peritoneal
cavity. Once metastasis has occurred, surgical removal of all
lesions is no longer possible, making ovarian cancer extremely
difficult to combat. The remaining first-line treatment option
is chemotherapy.
Cytoreductive surgery followed by platinum and
taxane‑based combination chemotherapy is currently the standard treatment for ovarian cancer (12). Ovarian cancer is one
of the most sensitive solid tumors, with objective responses
ranging from 60 to 80% to chemotherapy even in patients with
advanced stage disease. However, most patients ultimately
recur and develop resistance to chemotherapy. Resistance
to chemotherapy presents a major obstacle to improving the
prognosis of patients with ovarian cancer. The response rate to
current second-line or third-line (after interim non-platinum
therapy) chemotherapy is <33% due to the rise in resistance
to these drugs (13,14). Therefore, selecting new chemicals as
cancer therapeutics from natural compounds is still crucial for
ovarian cancer research. Finding new natural compounds that
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match or exceed the effects of common chemical drugs, or are
able to be given in combination with cisplatin to overcome
resistance is of great significance (15). Our previous studies
have shown that phenolic compounds are effective inhibitors
of cell growth and vascular endothelial growth factor (VEGF)
expression in ovarian cancer cells (16-18).
Gallic acid (3,4,5-trihydroxybenzoic acid, GA), a predominant polyphenol, is an endogenous plant polyphenol abundantly
found in tea, grapes, berries and other fruits as well as in wine.
GA has been shown to exhibit a variety of pharmacological
and biological properties, including antibacterial, antiviral,
and antitumor activities in many human cancer cell lines. Its
anticancer activity has been reported in oral (19), lung (20),
pancreatic (21), glioma (22) and cervical cancer cells (23).
In our previous experiments, we found that GA has the
greatest inhibitory activity on human ovarian cancer cells
among eight natural phenolic compounds from traditional
Chinese medicine (24). However, the molecular mechanisms
underlying the anti-angiogenic effects of GA on ovarian cancer
have not been discussed in detail to date. In the present study, the
inhibitory effect on cell proliferation, in vitro angiogenesis and
VEGF expression by GA on human ovarian cancer cell lines
was examined. In particular, the mechanism of GA-induced
anti‑angiogenesis in OVCAR-3 cells was further studied.
Materials and methods
Cell culture and treatment. Ovarian cancer cell line OVCAR-3
was provided by Dr BingHua Jiang of West Virginia University.
IOSE-364, normal ovarian surface epithelial cells from healthy
women, but immortalized with SV40 T/t, were courtesy of
Dr Auersperg of the University of British Columbia, Canada.
All cells were maintained in RPMI‑1640 medium (Sigma)
supplemented with 10% US-qualified fetal bovine serum
(Invitrogen, Grand Island, NY, USA) in a cell culture incubator with 5% CO2 at 37˚C. A stock solution of GA (Sigma)
was prepared in dimethyl sulfoxide (DMSO) at 100 mM and
stored at -20˚C. Different concentrations of GA were prepared
in RPMI-1640 medium for cell treatments, and DMSO was
included in the preparations to ensure equal concentrations of
DMSO in each treatment.
Cell viability assay. To measure cell viability, cells were
seeded in 96-well plates at a density of 1x104/well and allowed
to recover, attach to the substrate, and grown to log phase overnight. After incubation 37˚C, the culture medium was removed
and incubated with different concentrations of GA for 24 h.
Each treatment was performed in triplicate. After treatment,
the cells were washed twice with phosphate-buffered saline
(PBS), introduced to 100 µl freshly prepared AQueous One
Solution (MTS tetrazolium compound) (Promega, Madison,
WI, USA) in medium, and incubated for 1 h at 37˚C. The OD
values, at 490 nm, were measured by an enzyme-linked immunosorbent assay (ELISA) plate reader (Bio-Tek Instruments,
Winooski, VT, USA). Cell viability was expressed as a
percentage of the control.
VEGF protein quantification. The effect of GA on VEGF
protein secretion was analyzed by ELISA with a Quantikine
Human VEGF Immunoassay kit (R&D Systems, Minneapolis,

MN, USA), targeting VEGF165 in the cell culture supernatant.
Cells (6x105) were seeded in 60-mm cell culture dishes and
allowed to attach to the substrate and grow for 16 h at 37˚C
before treatment with various concentrations of GA for 24 h.
Culture supernatants were collected for the VEGF assay.
The inhibition of VEGF protein secretion was expressed as
a percentage of the control. Cell lysates were also assayed for
total protein levels using the BCA protein assay kit (Pierce,
Rockford, IL, USA) to adjust VEGF levels.
In vitro angiogenesis assay. OVCAR-3 cancer cells were
seeded in 60-mm cell culture dishes at 6x105 cells/dish and
incubated overnight. Cells were then treated with 4 ml
serum‑free medium containing 0, 5, 10, or 20 µM GA for
24 h and collected for the in vitro angiogenesis assay. Growth
factor-reduced Matrigel (BD Biosciences, San Jose, CA, USA)
was transferred into 96-well plates at 50 µl/well and incubated
at 37˚C for 1 h to gel. Human umbilical vein endothelial cells
(HUVECs) were harvested in PBS, counted, and seeded
onto the Matrigel beds at 2x104 cells/90 µl PBS. Thereafter,
volumes of 10 µl of the collected conditioned media were
added to each well. The system was incubated at 37˚C for 8 h,
and tube formation was visualized under a microscope with
images captured for comparison.
Western blot analysis. OVCAR-3 cancer cells were seeded and
incubated overnight before treatment with GA. After a double
wash with cold PBS, the cells were harvested with M-PER
Mammalian Protein Extraction reagent supplemented with
Halt protease and phosphatase inhibitor (both from Pierce),
and total protein levels were assayed with the BCA protein
assay kit. Cell lysates (50 µg total protein) were separated by
SDS-PAGE and blotted onto a nitrocellulose membrane with
a Mini-Protean 3 system (Bio‑Rad, Hercules, CA, USA). For
immunodetection, antibodies against HIF-1α, HIF-1β, AKT,
p-AKT, PTEN and GAPDH (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) were applied, and signals were visualized
with phycoerythrin-conjugated anti-mouse IgG secondary
antibodies, SuperSignal West Pico Substrate, and X-ray film
(Pierce). Protein bands were quantitated with NIH ImageJ
software and normalized by GAPDH bands for analysis.
Transient transfection and luciferase assay. OVCAR-3 cancer
cells (1x104 cells/well) were seeded onto 96-well plates and
incubated overnight. For transfection with hypoxia‑inducible
factor 1α (HIF-1α) plasmids (Addgene, Cambridge, MA,
USA), cells were transfected with VEGF luciferase reporter
(0.05 µg) and HIF-1α plasmids (0, 0.0625, 0.125 and 0.25 µg)
or SR-a (as vehicle) plasmids using 0.6 µl of jetPRIME reagent
(VWR, West Chester, PA, USA) for 4 h. For transfection with
mAkt plasmids (Addgene), the cells were transfected with
HIF-1α or VEGF luciferase reporter (0.05 µg) and mAkt (0,
0.0625, and 0.125 µg) or the SR-a plasmids using 0.6 µl of
jetPRIME reagent for 4 h. After transfection, all the cells
were treated with or without GA (5 µM) for 16 h. The cells
were harvested and analyzed for luciferase activity and total
protein levels using a BCA protein assay kit, and the activities
of VEGF reporter or the HIF-1α reporter were normalized to
corresponding total protein levels for statistical analysis. The
experiments were conducted 3-8 times.
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Figure 1. Gallic acid (GA) inhibits cell proliferation in OVCAR-3 and
A2780/CP70 ovarian cancer cells and ISOE 364 ovarian normal cells in a
dose-dependent manner. Data represents means ± SE from 4 independent
experiments. All data were analyzed by one-way ANOVA analysis followed
by Dunnett's test. *P<0.05 as compared to the control; **P<0.01 as compared
to the control.

Statistical analysis. One-way ANOVA followed by Dunnett's
test or by the Student's t-test was applied to compare the
effects between chemical treatments. A p-value of <0.05 was
considered as indicative of a statistically significant result.
Results and Discussion
GA inhibits cell proliferation and VEGF secretion
dose‑dependently in an ovarian cancer cell line. Phenolic
compounds, a large family of natural compounds with
phenolic hydroxyls found in plants, fruits, vegetables and teas,
have long been regarded as significant secondary metabolites
for their chemopreventive and chemotherapeutic effects in
cancer (25,26). In our previous experiments, eight natural
phenolic compounds from traditional Chinese medicine were
compared for their anti-proliferative effects on an ovarian
cancer cell line at concentrations of 20 and 40 µM using a cell
viability assay. We found that GA had the greatest inhibitory
activity among these phenolic compounds (24). Therefore, GA
was selected for subsequent experiments. Yet, we needed to
clarify the appropriate dosage of GA needed to exert significant effects and to determine the relative cytotoxic effects on
ovarian cancer cell lines compared to normal ovarian cells.
In the present study, we further examined the suppression
of cell viability after treatment with varying concentrations
of GA (0, 5, 10, 20 and 40 µM) in ovarian cancer cell lines
(OVCAR-3, A2780/CP70) and in a normal ovarian cell line
(ISOE-364).
As shown in Fig. 1, an overall inhibitory effect of GA on
ovarian cancer cell lines and the normal ovarian cell line was
tested. A2780/CP70 cell viability was significantly inhibited
to 30.10% at 40 µM GA treatment. The inhibitory effect on
OVCAR-3 cells was much higher than that on the A2780/CP70
cells. OVCAR-3 cell viability was inhibited to 66.86 and 2.11%
by 20 and 40 µM GA treatment, respectively. Compared to
the inhibitory effect of cisplatin at 20 µM (16), the lower
cell viabilities demonstrate that GA has high potential in the
prevention and therapy of ovarian cancer.

Figure 2. The effect of gallic acid (GA) on VEGF expression and in vitro
angiogenesis in ovarian cancer cell lines. (A) GA inhibited VEGF secretion in OVCAR-3 and A2780/CP70 cells in a dose-dependent manner. The
inhibitory effects on A2780/CP70 cells treated with 10 and 20 µM GA were
different from the control but they were not significant (P= 0.116 and 0.095,
respectively). Data represents the means ± SE from three independent experiments. All data were analyzed by one-way ANOVA analysis followed by
Dunnett's test. *P<0.05 as compared to the control; **P<0.01 as compared to
the control. (B) GA inhibits in vitro angiogenesis in OVCAR-3 cancer cells.

Notably, GA did not have a significant inhibitory effect on
the normal cell line (IOSE-364) at 40 µM. This result indicates
that the inhibitory effects of GA on normal ovarian cells were
less than that on the ovarian cancer cells. Therefore, GA selectively inhibits cancer cells while having significantly weaker
inhibitory effects on normal ovarian cells.
Many polyphenols have poor bioavailability, with about
a 100-1,000 nM concentration in human serum. However,
analyses of the bioavailability of polyphenols in humans
reveal that GA performs better than other polyphenols (27). A
concentration of ~8-10 µM of GA was detected in the serum
of healthy volunteers, after oral intake of a combination of
a dietary herbal supplement and 800 mg GA (28). The GA
concentration found in this study is very close to therapeutic
concentrations. A slight decrease in cell viability at 10 µM GA
treatment was also observed, although this decrease did not
reach statistical significance.
VEGF is the best studied and the most potent pro-angiogenic
factor known (29,30). For the purpose of angio-prevention,
levels of VEGF were examined. As shown in Fig. 2A, VEGF
expression in the A2780/CP70 cells and OVCAR-3 cells with
40 µM GA treatment was significantly inhibited to 24.05
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Figure 3. The effect of gallic acid (GA) on HIF-1α and HIF-1β protein expression in OVCAR-3 cells and luciferase assay after transfection with VEGF
luciferase reporter and HIF-1α plasmids. (A) GA decreases HIF-1α protein expression. Data represents mean ± SE from 4 independent experiment. (B) HIF-1α
mediates the inhibitory effect by GA on VEGF transcriptional activation. Data represents means ± SE from 6 independent experiments. **P<0.01 as compared
to the control.

and 27.12%, respectively. The inhibitory effect on OVCAR-3
cells increased significantly when the concentrations were
>5 µM while for A2780/CP70 cells the concentrations were
>40 µM. Levels of VEGF excreted by OVCAR-3 cancer cells
were inhibited to 82.75, 79.22, 68.88, and 27.12% by 5, 10, 20,
and 40 µM GA treatments, respectively.
The inhibitory effect of GA on the OVCAR-3 cells was
more pronounced than that on the A2780/CP70 cells. As
shown in Fig. 2A, the inhibitory effects on A2780/CP70 cells
treated with 10 and 20 µM GA were different from the control
but they were not significant. This may be due to the lack of
functional DNA mismatch repair of A2780/CP70 cells, which
hampers the inhibitory effect of GA (31).
Since 8 to 10 µM of GA in the blood is attainable in humans
following a plant-rich diet, our research suggests that GA can
directly inhibit VEGF secretion of ovarian cancer cells at
physiologically relevant concentrations. This is an exciting
result which indicates that GA may have legitimate potential
in treating cancer patients in the clinic.
GA inhibits in vitro angiogenesis induced by OVCAR-3 in
ovarian cancer cells. Angiogenesis, the formation of new
blood vessels, is essential for tumor development and subsequent growth, invasion and metastasis. Suppressed expression
of VEGF by kaempferol and chaetoglobosin K has been shown
to inhibit in vitro angiogenesis in our previous research (17,32).
GA may have a similar effect of inhibiting tube formation by
HUVECs induced by VEGF. Therefore, we investigated the
effect of GA on in vitro tube formation by HUVECs induced
by the culture medium of ovarian cancer cells treated with
different concentrations of GA. We found that the culture
media conditioned by OVCAR-3 ovarian cancer cells promoted
in vitro angiogenesis and presented a well-established network
of HUVECs (Fig. 2B). Following treatment with increasing
concentrations of GA treatment, the network was scattered

down and HUVECs gradually lost their ability to form tube
structures. A 20-µM GA treatment completely destroyed the
network structure, and HUVECs were presented as mostly
individual clumps. Similar to other compounds in our earlier
research, GA inhibits in vitro angiogenesis through suppression of VEGF expression.
GA inhibits VEGF production through downregulation of
HIF-1α expression. It has been well established that hypoxia
stimulates transcriptional activation of VEGF through induction of HIF-1α, and HIF-1α is considered a primary regulator
of VEGF production. Thus, we first examined the influence
of GA treatment on HIF-1α expression. It is generally thought
that HIF-1α is regulated mainly by low oxygen or hypoxia as
its name indicates. However, in concordance with our previous
findings, HIF-1α is highly expressed in normoxic conditions
in ovarian cancer cells (32). As expected, the protein levels
of HIF-1α in the OVCAR-3 cancer cell line were markedly
decreased with higher concentrations of GA. At 20 µM, the
protein levels of HIF-1α were 23.48% of the levels of HIF-1β.
This means that GA effectively decreased the protein expression of HIF-1α. These results suggest that HIF-1α may be
involved in the inhibitory mechanism of VEGF production
by GA treatment. To confirm that HIF-1α expression is not
only regulated by GA treatment but also plays a role in the
inhibition of VEGF secretion by GA, OVCAR-3 cells were
transfected with the VEGF-promoter reporter, together with
HIF-1α plasmids. As shown in Fig. 3B, this inhibition of VEGF
was significantly reversed by forced expression of the HIF-1α
protein. The higher the expression of HIF-1α, the higher the
increase in the expression of the VEGF reporter. These results
demonstrated that GA inhibits VEGF production through a
HIF-1α-dependent pathway.
The transcription factor HIF-1 consists of two subunits,
HIF-1α and HIF-1β. Research has shown that HIF-1β may be
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Figure 5. Gallic acid (GA) decreases p-AKT protein expression in OVCAR-3
cells. Data represents mean ± SE from 5 independent experiments. *P<0.05
as compared to the control.

Figure 4. The effect of gallic acid (GA) on p-AKT and AKT protein expression in OVCAR-3 cells and luciferase assay after transfection with mAKT
plasmids and VEGF luciferase reporter or HIF-1α luciferase reporter.
(A) GA decreases p-AKT protein expression in OVCAR-3 cells. Data represents mean ± SE from 5 independent experiment. (B) mAKT mediates the
inhibitory effects of GA on VEGF expression in ovarian cancer cells. Data
represents mean ± SE from 8 independent experiment. (C) mAKT mediates
the inhibitory effects of GA on HIF-1α expression in ovarian cancer cells.
Data represents mean ± SE from 4 independent experiments. *P<0.05 as
compared to the control; **P<0.01 as compared to the control.

regulated through an HIF-1α-dependent pathway (33). Thus,
the protein levels of HIF-1β were also investigated. As shown
in Fig. 3A, GA did not have a significant effect on the expression of HIF-1β. As generally regarded, HIF-1β is constitutively
expressed in ovarian cancer cells. GA inhibits VEGF production through transcription factor, HIF-1, by reducing the
expression of HIF-1α.

GA inhibits HIF-1α expression through blocking the phos‑
phorylation of AKT. It is commonly recognized that the
PI3K pathway plays an important role in the regulation of
cell growth, motility, survival and metabolism, as well as
angiogenesis. AKT, identified as an oncogene in the 1980's,
serves as a central sensor in the PI3K pathway and represents an attractive therapeutic target since multiple signaling
components converge in AKT (34). To check whether the
inhibition of the expression of HIF-1α and VEGF protein
by GA is mediated by the AKT pathway, we first examined
the levels of AKT and p-AKT protein after GA (0, 5, 10 and
20 µM) treatment. As shown in Fig. 4A, the protein levels of
p-AKT in the OVCAR-3 cancer cell line were decreased with
higher concentrations of GA while no significant change in the
protein levels of AKT was found. These results demonstrate
that GA inhibits the phosphorylation of AKT. To show that
the activation of AKT plays a role in the inhibition of HIF-1α
and VEGF secretion by GA, OVCAR-3 cells were transfected
with the HIF-1α promoter reporter, together with the mAKT
plasmids. As shown in Fig. 4B and C, the inhibition of HIF-1α
and VEGF was significantly reversed by forced expression of
the mAKT protein, and the higher the expression of mAKT,
the higher the expression of the HIF-1α reporter and VEGF
reporter. These results demonstrate that GA inhibits HIF-1α
and VEGF expression through blocking the phosphorylation
of AKT. The regulating effect of AKT on HIF-1α or VEGF
expression in ovarian cancer cells was also reported (35,36).
Research into how the PI3K/AKT/mTOR pathway affects the
progression and tumorigenesis of ovarian cancer may lead to
new therapies that will increase the survival of these patients
(37). The inhibitory effect of GA on the PI3K/Akt pathway
demonstrates great therapeutic potential for ovarian cancer.
GA upregulates PTEN expression in OVCAR-3 ovarian
cancer cells. Phosphatase and tensin homolog deleted on
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inhibitory effect of GA may be involved in the suppression of
AKT phosphorylation and upregulation of PTEN expression.
A mechanism/pathway for the inhibition of VEGF expression
by GA in ovarian cancer cells is proposed (Fig. 6). These findings enhance our understanding of its mechanism of action
and provide strong support for using this compound in future
animal and clinical studies.
AKT is an important serine-threonine protein kinase and
carries out various cellular functions such as angiogenesis,
cell metabolism, cell survival/inhibition of apoptosis, and the
cell cycle. The inhibition of AKT phosphorylation by GA may
imply that GA induces various other cellular functions that
require further study.
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